AlloVir, Inc.
AlloVir, Inc. (ALVR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ALVR · as of Dec 31, 2024
Ownership Breakdown
48
Institutional Holders
▼ 14 vs Q3
$19.74M
Total Inst. Value
▼ $16.54M vs Q3
5.04M
Shares Outstanding
freeFloat 17.31%
38.01M
13F Shares Held
▼ 6.87M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ALVR largest shareholders · institutional ownership
Q4 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GILEAD SCIENCES, INC. biological products, (no diagnostic substances) | 16.64M | 62.68% | 62.68% | $6.99B | Feb 13, 2025 | NEW |
SIREN, L.L.C. biological products, (no diagnostic substances) | 6.60M | 24.86% | 24.86% | $2.77B | Feb 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 3.03M | 11.43% | 11.43% | $1.27B | Feb 14, 2025 | ▼ 251.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.65M | 9.97% | 9.97% | $1.11B | Feb 11, 2025 | — held |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 1.91M | 7.19% | 7.19% | $801.35M | Feb 14, 2025 | — held |
JACOBS LEVY EQUITY MANAGEMENT, INC biological products, (no diagnostic substances) | 664.4K | 2.50% | 2.50% | $279.06M | Feb 14, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 632.9K | 2.38% | 2.38% | $265.81M | Feb 7, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 584.8K | 2.20% | 2.20% | $245.69M | Feb 12, 2025 | ▼ 767 |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 552.3K | 2.08% | 2.08% | $231.95M | Feb 14, 2025 | NEW |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 496.5K | 1.87% | 1.87% | $208.53M | Feb 14, 2025 | ▼ 11.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2024 vs prior quarter
Q4 2024
11
Increased
+374.8K shares10
New Positions
first time holders17
Decreased
−12.19M shares2
Sold Out
fully exitedNet shares change (top 50)
11.81M
+374.8K / −12.19M
Net new holders
+2
10 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ALVR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
20
Sell transactions
0.05
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sinha Vikas See Remarks | Feb 21, 2025 | Sale | 303 | $10.08 | $3.1K | 49.1K | Form 4 ↗ |
Hagen Brett R Chief Accounting Officer | Feb 21, 2025 | Sale | 96 | $10.08 | $967.277 | 2.8K | Form 4 ↗ |
Miller Edward General Counsel | Feb 21, 2025 | Sale | 106 | $10.08 | $1.1K | 6.5K | Form 4 ↗ |
Miller Edward General Counsel | Jan 23, 2025 | Sale | 47 | $9.45 | $444.329 | 6.6K | Form 4 ↗ |
Miller Edward General Counsel | Jan 23, 2025 | Sale | 5 | $9.94 | $49.701 | 6.6K | Form 4 ↗ |
Hagen Brett R Chief Accounting Officer | Jan 23, 2025 | Sale | 32 | $9.45 | $302.522 | 2.9K | Form 4 ↗ |
Hagen Brett R Chief Accounting Officer | Jan 23, 2025 | Sale | 4 | $9.94 | $39.761 | 2.9K | Form 4 ↗ |
Sinha Vikas See Remarks | Jan 23, 2025 | Sale | 116 | $9.45 | $1.1K | 49.4K | Form 4 ↗ |
Sinha Vikas See Remarks | Jan 23, 2025 | Sale | 13 | $9.94 | $129.223 | 49.4K | Form 4 ↗ |
Miller Edward General Counsel | Jan 10, 2025 | Sale | 409 | $0.44 | $180.001 | 153.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
AlloVir, Inc. (ALVR) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 82.69%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of AlloVir, Inc. is GILEAD SCIENCES, INC., holding approximately 16.64 million shares — equal to 62.68% of outstanding shares — as of December 31, 2024.
A total of 48 institutional investors currently hold ALVR stock, with a combined institutional value of approximately $19,739,441 as of the most recent 13F filing period.
Frequently asked questions
ALVR ownershipAlloVir, Inc. (ALVR) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is GILEAD SCIENCES, INC. with a 62.68% stake. Company insiders hold 82.69%. Data sourced from SEC Form 13F as of December 31, 2024.